Ethermed | $8,500,000 | (Apr 17, 2026)
Joyful Health | $17,000,000 | (Apr 17, 2026)
Worki.ai | $2,750,000 | (Apr 17, 2026)
Certified by Founder
Lodge
Curevo Vaccine
start up
United States
- Bothell, Washington
- 19/03/2025
- Series B
- $110,000,000
Curevo Vaccine is a clinical-stage developer of vaccines for varicella and herpes zoster. Amezosvatein (CRV-101) is an adjuvanted subunit (non-mRNA) vaccine designed to prevent herpes zoster, commonly known as shingles. Our goal with a new herpes zoster vaccine is to improve the patient experience and, ultimately, overall vaccination rates, by developing amezosvatein as a vaccine with non-inferior efficacy combined with clinically-meaningful improvements in reactogenicity when compared to Shingrix.
- Industry Biotechnology Research
- Website https://curevovaccine.com/
- LinkedIn https://www.linkedin.com/company/curevovaccine/
Related People
George SimeonFounder
United States -
Greater Seattle Area
Strategic Alliances, Global Commercialisation, M&A, Joint-Ventures, Organization Building
Balance between: Strategic Thinking - Creative Problem Solving - 'Hands-on' Execution
Balerion AI | $6,000,000 | (Apr 17, 2026)
Beeline Medicines | $300,000,000 | (Apr 17, 2026)
Expo | $45,000,000 | (Apr 17, 2026)
Sepion Technologies | $10,000,000 | (Apr 17, 2026)
Lua AI (YC F25) | $5,800,000 | (Apr 17, 2026)
Nas.com | $27,000,000 | (Apr 17, 2026)
Resolv | $1,000,000 | (Apr 17, 2026)
Solidroad | $25,000,000 | (Apr 17, 2026)
Parasail | $32,000,000 | (Apr 16, 2026)